AU2003285946A1 - Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases - Google Patents

Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases

Info

Publication number
AU2003285946A1
AU2003285946A1 AU2003285946A AU2003285946A AU2003285946A1 AU 2003285946 A1 AU2003285946 A1 AU 2003285946A1 AU 2003285946 A AU2003285946 A AU 2003285946A AU 2003285946 A AU2003285946 A AU 2003285946A AU 2003285946 A1 AU2003285946 A1 AU 2003285946A1
Authority
AU
Australia
Prior art keywords
antimycobacterial
targets
inhibition
identification
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003285946A
Other versions
AU2003285946A8 (en
Inventor
Andrew Brian Avarbock
David Howard Avarbock
Harvey Rubin
Edward Weinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of AU2003285946A1 publication Critical patent/AU2003285946A1/en
Publication of AU2003285946A8 publication Critical patent/AU2003285946A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
AU2003285946A 2002-10-22 2003-10-22 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases Abandoned AU2003285946A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42013102P 2002-10-22 2002-10-22
US60/420,131 2002-10-22
PCT/US2003/033524 WO2004037192A2 (en) 2002-10-22 2003-10-22 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases

Publications (2)

Publication Number Publication Date
AU2003285946A1 true AU2003285946A1 (en) 2004-05-13
AU2003285946A8 AU2003285946A8 (en) 2004-05-13

Family

ID=32176517

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003294235A Abandoned AU2003294235A1 (en) 2002-10-22 2003-10-22 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof
AU2003285946A Abandoned AU2003285946A1 (en) 2002-10-22 2003-10-22 Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2003294235A Abandoned AU2003294235A1 (en) 2002-10-22 2003-10-22 Fragments and activity of rel protein in m. tuberculosis adn other uses thereof

Country Status (2)

Country Link
AU (2) AU2003294235A1 (en)
WO (2) WO2004037192A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109385439A (en) * 2018-09-18 2019-02-26 上海晶诺生物科技有限公司 The one recombination TM4 phage library and its application for constructing nadh dehydrogenase gene family missing mycobacterium tuberculosis

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246349A1 (en) * 2009-04-20 2010-11-03 BKG Pharma ApS Treatment of infectious diseases
ES2642586T3 (en) 2009-07-27 2017-11-16 Gilead Sciences, Inc. Condensed heterocyclic compounds as ion channel modulators
PT2588197E (en) 2010-07-02 2015-02-09 Gilead Sciences Inc Fused heterocyclic compounds as ion channel modulators
MX361350B (en) 2011-05-10 2018-12-04 Gilead Sciences Inc Fused heterocyclic compounds as sodium channel modulators.
TW201837023A (en) 2011-07-01 2018-10-16 美商基利科學股份有限公司 Fused heterocyclic compounds as ion channel modulators
NO3175985T3 (en) 2011-07-01 2018-04-28
EP2758403B1 (en) 2011-09-21 2016-04-27 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN103232447B (en) * 2013-04-02 2015-06-03 陕西科技大学 3-acetyl-5-acetylimino-2-(N-phenothiazinyl)-1,3,4-thiadiazole, and preparation method and application thereof
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
WO2023201199A2 (en) * 2022-04-11 2023-10-19 The Johns Hopkins University Tuberculosis vaccines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834279A (en) * 1996-03-07 1998-11-10 Trustees Of The University Of Pennsylvania Methods of identifying compounds that inhibit DNA synthesis in mycobacterium tuberculosis and compositions, reagents and kits for performing the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109385439A (en) * 2018-09-18 2019-02-26 上海晶诺生物科技有限公司 The one recombination TM4 phage library and its application for constructing nadh dehydrogenase gene family missing mycobacterium tuberculosis

Also Published As

Publication number Publication date
WO2004037192A2 (en) 2004-05-06
WO2004037997A2 (en) 2004-05-06
AU2003294235A8 (en) 2004-05-13
WO2004037997A3 (en) 2004-11-18
AU2003294235A1 (en) 2004-05-13
WO2004037192A3 (en) 2006-09-14
AU2003285946A8 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2003249716A1 (en) Method and system for increasing the efficacy of a clinical trial
AU2003235613A1 (en) Crude drug compositions for treating or preventing arthritic diseases and the preparation process
AU2003291992A1 (en) Phenylethanolamine derivatives for the treatment of respiratory diseases
AU2003256253A1 (en) Aerosol for medical treatment and methods
AU2002366355A1 (en) SEQUESTRATION OF ABeta IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
HRP20040906B1 (en) Bisphosphonic acid for the treatment and prevention of ostreoporosis
AU2003229923A1 (en) Curcumin for the prevention and/or treatment of tissue damage
AU2003289330A1 (en) Preventives and/or remedies for central diseases
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2003205771A1 (en) A method for the wet treatment of disk-like objects
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
AU2003285946A1 (en) Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases
AU2002220266A1 (en) Methods for the identification and the treatment of cardiovascular disease
AU2003241599A1 (en) Compositions and methods for the treatment of hemophilia a
AU2003249930A1 (en) Proteaseome inhibitors for the treatment of herpesviridae infected individuals
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases
AU2003292852A1 (en) A group of nucleic acid fragments for prevention of hiv infection or aids and the usage thereof
GB0201025D0 (en) The treatment of degenerative diseases
AU2002343085A1 (en) Tnf-alpha inhibitors for the treatment of hepatic diseases
AU2003210386A1 (en) Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases
AU2003287388A1 (en) Inhibition of hiv-1 replication
AU2003214317A1 (en) Use of a novel class of drugs for the treatment of parasitic diseases
AU2003255477A1 (en) Caspase 10 as target for monitoring and treatment of diseases
AUPS243002A0 (en) Therapeutic target and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase